Afficher la notice abrégée

Blood Telomere Length Changes After Ritonavir-Boosted Darunavir Combined With Raltegravir or Tenofovir-Emtricitabine in Antiretroviral-Naive Adults Infected With HIV-1

dc.rights.licenseopenen_US
dc.contributor.authorSTELLA-ASCARIZ, N.
dc.contributor.authorMONTEJANO, R.
dc.contributor.authorRODRIGUEZ-CENTENO, J.
dc.contributor.authorALEJOS, B.
hal.structure.identifierInstitut de biochimie et génétique cellulaires [IBGC]
dc.contributor.authorSCHWIMMER, Christine
dc.contributor.authorBERNARDINO, J. I.
dc.contributor.authorRODES, B.
dc.contributor.authorALLAVENA, C.
dc.contributor.authorHOFFMANN, C.
dc.contributor.authorGISSLEN, M.
dc.contributor.authorDE MIGUEL, R.
dc.contributor.authorESTEBAN-CANTOS, A.
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorWALLET, Cedrick
dc.contributor.authorRAFFI, F.
dc.contributor.authorARRIBAS, J. R.
dc.date.accessioned2021-01-05T13:52:53Z
dc.date.available2021-01-05T13:52:53Z
dc.date.issued2018-10-05
dc.identifier.issn1537-6613 (Electronic) 0022-1899 (Linking)en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/23667
dc.description.abstractEnBackground. Tenofovir is a potent inhibitor of human telomerase. The clinical relevance of this inhibition is unknown. Methods. NEAT001/ANRS143 is a randomized trial that showed noninferiority over 96 weeks of ritonavir-boosted darunavir plus raltegravir versus tenofovir disoproxil fumarate/emtricitabine in 805 antiretroviral antiretrovrial-naive HIV-infected adults. We compared changes in whole-blood telomere length measured with quantitative polymerase chain reaction in 201 randomly selected participants (104 raltegravir and 97 tenofovir disoproxil fumarate/emtricitabine). We performed multivariable estimative and predictive linear regression. Results. At week 96, participants receiving tenofovir disoproxil fumarate/emtricitabine had a statistically significant higher gain in telomere length than participants receiving raltegravir. Difference in mean telomere length change between groups (tenofovir disoproxil fumarate/emtricitabine minus raltegravir) from baseline to week 96 adjusted by baseline telomere length was 0.031 (P = .009). This difference was not significantly confounded by age, gender, known duration of HIV infection, CD4 (baseline/nadir), CD8 cells, CD4/CD8 ratio, HIV viral load (baseline/week 96), tobacco and alcohol consumption, statins, or hepatitis C. Conclusion. Antiretroviral-naive HIV-infected adults receiving ritonavir-boosted darunavir and tenofovir disoproxil fumarate/emtricitabine had a significant higher gain in blood telomere length than those receiving ritonavir-boosted darunavir and raltegravir, suggesting a better initial recovery from HIV-associated immunosenescence.
dc.language.isoENen_US
dc.subject.enPharmacoEpi-Drugs
dc.title.enBlood Telomere Length Changes After Ritonavir-Boosted Darunavir Combined With Raltegravir or Tenofovir-Emtricitabine in Antiretroviral-Naive Adults Infected With HIV-1
dc.title.alternativeJ Infect Disen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1093/infdis/jiy399en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed29982509en_US
bordeaux.journalJournal of Infectious Diseasesen_US
bordeaux.page1523-1530en_US
bordeaux.volume218en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.issue10en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.teamPharmacoEpi-Drugsen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-03193819
hal.version1
hal.date.transferred2021-04-09T07:50:54Z
hal.exporttrue
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Journal%20of%20Infectious%20Diseases&rft.date=2018-10-05&rft.volume=218&rft.issue=10&rft.spage=1523-1530&rft.epage=1523-1530&rft.eissn=1537-6613%20(Electronic)%200022-1899%20(Linking)&rft.issn=1537-6613%20(Electronic)%200022-1899%20(Linking)&rft.au=STELLA-ASCARIZ,%20N.&MONTEJANO,%20R.&RODRIGUEZ-CENTENO,%20J.&ALEJOS,%20B.&SCHWIMMER,%20Christine&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée